Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

[1]  L. Cascione,et al.  The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.

[2]  Rameen Beroukhim,et al.  Sound credit scores and financial decisions despite cognitive aging , 2014, Proceedings of the National Academy of Sciences.

[3]  B. Stack,et al.  BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. , 2014, Cancer research.

[4]  T. Misteli,et al.  Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4. , 2014, Cell reports.

[5]  Jessica E. Bolden,et al.  Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition , 2014, Cell reports.

[6]  Paul Shinn,et al.  Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.

[7]  Jeremy L. Jenkins,et al.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.

[8]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[9]  D. Felsher,et al.  MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.

[10]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[11]  B. Nadel,et al.  Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL) , 2014, Oncotarget.

[12]  Dennis L. Buckley,et al.  Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. , 2014, Angewandte Chemie.

[13]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[14]  Charles Y. Lin,et al.  Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.

[15]  R. Vessella,et al.  Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer , 2013, Oncotarget.

[16]  J. Noel,et al.  Abstract C244: Development of the BET bromodomain inhibitor OTX015. , 2013 .

[17]  Travis J Cohoon,et al.  Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[18]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[19]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[20]  A. Belkina,et al.  BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.

[21]  P. Workman,et al.  Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.

[22]  M. Frech,et al.  Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding , 2012, Leukemia.

[23]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[24]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[25]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[26]  J. Burnett,et al.  Current progress of siRNA/shRNA therapeutics in clinical trials , 2011, Biotechnology journal.

[27]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[28]  B. Cravatt,et al.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.

[29]  T. Wirth,et al.  Advances in the understanding of MYC‐induced lymphomagenesis , 2010, British journal of haematology.

[30]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[31]  C. Crews,et al.  Chemical Inducers of Targeted Protein Degradation* , 2010, The Journal of Biological Chemistry.

[32]  J. Aster,et al.  BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells , 2008, Oncogene.

[33]  C. Crews,et al.  Chemical Approaches to Controlling Intracellular Protein Degradation , 2005, Chembiochem : a European journal of chemical biology.

[34]  Michael A. Koldobskiy,et al.  Chemical genetic control of protein levels: selective in vivo targeted degradation. , 2004, Journal of the American Chemical Society.

[35]  A. Howell,et al.  The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. , 2004, Best practice & research. Clinical endocrinology & metabolism.

[36]  A. Ransick,et al.  Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation* , 2003, Molecular & Cellular Proteomics.

[37]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.